$19.2M in cash against a market cap in the same range. Aramchol Phase 3 open-label completed with 65% fibrosis improvement at week 48. GI oncology program entering Phase 1/2 in early 2026. The pipeline is priced at zero or below.
Galmed holds approximately $19.2M in cash with virtually no debt as of Q3 2025. The quarterly burn rate is approximately $1.5M. That gives the company a cash runway of approximately 12 quarters at current burn; three years; before needing additional capital. The market cap (share price multiplied by shares outstanding) has at various points traded below the cash position, meaning the pipeline was being valued at zero or negative. The Phase 3 open-label Aramchol program just posted 65 percent fibrosis improvement at week 48, with AI evaluation showing 100 percent improvement.
Aramchol's mechanism targets SCD1, an enzyme involved in fatty acid metabolism in the liver. The ARMOR Phase 3 open-label study is complete. A sublingual formulation is in development with a term sheet signed for combination with semaglutide; the GLP-1 agonist class that has dominated metabolic disease treatment conversations. The GI oncology program; targeting colorectal cancer, hepatocellular carcinoma, and cholangiocarcinoma; is entering Phase 1/2 in early 2026 based on pre-clinical combination data with regorafenib.
The Human Translation: The Car for Less Than the Parts Are Worth. You can buy the entire company for roughly what the cash is worth; or less. The clinical programs cost nothing extra because the market has assigned them no value. If the Phase 1/2 GI oncology program produces any signal at all, or if a partnership for the sublingual semaglutide combination is announced, the implied value of the pipeline goes from zero to something. Any number above zero is upside on what you paid.
Galmed has also announced a Bitcoin treasury strategy, allocating up to 50 percent of cash to Bitcoin as a shareholder value initiative. This is either a creative capital allocation decision or a red flag depending on perspective; but it does not change the clinical value of the Aramchol pipeline, which exists independently of how the cash is managed.
The quarterly net loss was approximately $2.0M in Q3 2025, broken roughly evenly between R&D ($0.6M) and G&A ($0.6M). With $19.2M in cash and a $1.5M quarterly burn, the company has substantial runway to reach multiple clinical inflection points without a dilutive capital raise.
The cash-to-market-cap relationship is the most immediately striking analytical feature of Galmed. With approximately $19.2M in cash and virtually no debt, the company cash position has at various points exceeded or closely matched its entire market capitalization. When a company market cap approaches its cash balance, the market is implicitly assigning zero or negative value to everything else the company owns; its intellectual property, its clinical data, its pipeline, its team, its regulatory relationships. In Galmed case, that means the market is assigning zero value to Aramchol Phase 3 open-label data showing 65 percent fibrosis improvement at week 48, the GI oncology program entering Phase 1/2, and the sublingual semaglutide combination term sheet. Either the market has concluded these assets are worthless, or the market has not evaluated them at all. The second explanation is more likely in a micro-cap biotech with no sell-side coverage.
Aramchol mechanism of action targets SCD1, an enzyme involved in fatty acid metabolism in the liver. The scientific rationale is direct: NASH is characterized by excessive fat accumulation in liver cells, leading to inflammation, fibrosis, and eventually cirrhosis or hepatocellular carcinoma. By modulating the enzyme responsible for fatty acid synthesis, Aramchol aims to address the root metabolic dysfunction rather than treating downstream symptoms. The ARMOR Phase 3 open-label study demonstrated 65 percent fibrosis improvement at week 48 using standard histological assessment, and 100 percent improvement using AI-based evaluation. The discrepancy between standard and AI evaluation is worth noting; it suggests the AI assessment may be detecting improvements that traditional pathologist review misses, which is scientifically plausible given the quantitative precision of computational image analysis versus subjective human grading.
The sublingual formulation development and the semaglutide combination term sheet represent the strategic pivot that could transform Galmed from a single-asset biotech into a platform positioned at the intersection of two massive therapeutic markets. Semaglutide; the GLP-1 agonist marketed as Ozempic and Wegovy; has become the most commercially successful drug class in metabolic disease. A combination product that pairs Aramchol liver-targeted mechanism with semaglutide systemic metabolic effects could address NASH from two complementary angles. The term sheet signals that a partner has evaluated the scientific rationale and found it compelling enough to negotiate commercial terms. The sublingual formulation; designed to be dissolved under the tongue rather than swallowed; improves bioavailability and patient compliance compared to oral tablets.
The GI oncology program represents a second clinical vertical that diversifies the pipeline beyond liver disease. The program targets colorectal cancer, hepatocellular carcinoma, and cholangiocarcinoma using Aramchol SCD1 inhibition mechanism in combination with regorafenib, an existing cancer drug. Preclinical combination data supported the Phase 1/2 filing planned for early 2026. If the Phase 1/2 produces any positive safety and efficacy signal, the implied value of the pipeline changes from zero; where the market currently prices it, to something calculable based on comparable oncology assets at similar clinical stages. GI oncology assets in Phase 1/2 with positive preliminary data typically attract partnership interest from mid-size pharmaceutical companies looking to supplement their oncology pipelines.
The Bitcoin treasury strategy is the most controversial element of the Galmed investment thesis. Management announced an allocation of up to 50 percent of cash to Bitcoin as a shareholder value initiative. For a clinical-stage biotech with $19.2M in cash and a multi-year runway predicated on that cash lasting until clinical milestones are achieved, converting a significant portion of the treasury to a volatile asset introduces balance sheet risk that did not previously exist. If Bitcoin appreciates, the treasury grows and the runway extends. If Bitcoin declines 40 percent; which it has done multiple times in its history; the effective cash runway shortens materially and the ability to fund clinical programs without dilutive capital raises is compromised. This is a management decision that reasonable investors can evaluate very differently depending on their view of Bitcoin as a treasury asset.
The quarterly cash burn rate of approximately $1.5M gives Galmed roughly 12 quarters of runway at current spending; three years. Assuming no additional revenue, partnerships, or capital raises. That runway is sufficient to reach the Phase 1/2 GI oncology initiation, the sublingual semaglutide combination development milestones, and multiple data readouts from ongoing programs. The ability to reach clinical inflection points without needing to raise dilutive capital is the financial advantage that the cash position provides. Every clinical milestone achieved on existing cash is a milestone achieved without reducing existing shareholders ownership percentage. For a micro-cap biotech, where dilutive raises at depressed valuations can destroy shareholder value even when the science works, this financial independence is a genuinely valuable asset.
The NASH therapeutic landscape provides important context for Aramchol positioning. The NASH market has been described as a graveyard for drug developers; multiple large pharmaceutical companies have failed Phase 3 trials targeting NASH, including Intercept Pharmaceuticals whose obeticholic acid was rejected by the FDA. Madrigal Pharmaceuticals received accelerated approval for resmetirom (Rezdiffra) in early 2024, making it the first FDA-approved NASH treatment, but the market opportunity remains vast with an estimated 15 to 20 million Americans affected and the majority undiagnosed. Aramchol mechanism. SCD1 inhibition targeting hepatic fatty acid metabolism. Is mechanistically differentiated from resmetirom thyroid hormone receptor agonism. The combination potential is particularly relevant: a sublingual Aramchol formulation combined with semaglutide would pair two mechanistically distinct approaches in a fixed-dose combination, which has historically been the model for successful metabolic disease treatments. The term sheet for the semaglutide combination suggests that at least one potential partner has evaluated this logic and found it commercially viable.
The per-share cash analysis provides a useful framework for evaluating downside protection. With approximately $19.2M in cash and roughly 2.28M fully diluted shares, the cash per share is approximately $8.42. This establishes a theoretical floor; in a liquidation scenario, shareholders would receive approximately $8.42 per share from the cash alone before any value attribution to the clinical pipeline. In practice, liquidation rarely produces full recovery of stated cash per share, but the analysis illustrates the margin of safety when the stock trades near or below this level. The clinical pipeline. Phase 3 data in NASH, Phase 1/2 oncology program, semaglutide combination; is optionality that costs nothing above the cash floor. The risk-reward asymmetry is the core of the investment case: limited downside bounded by cash per share, with multiple potential clinical catalysts that could generate substantial upside if any one of them produces positive results or partnership activity.
The management team capital allocation discipline through this period deserves recognition alongside the legitimate criticism of the Bitcoin treasury decision. Galmed has maintained a quarterly burn rate of approximately $1.5M; remarkably lean for a clinical-stage biotech advancing multiple programs. Many comparable companies burn $5-10M per quarter on R&D and G&A expenses. The lean operating structure means that the $19.2M cash position provides roughly 12 quarters of runway, whereas a company with a $5M quarterly burn would have less than four quarters. This capital efficiency is a management decision that directly impacts shareholder value by extending the runway to clinical milestones without dilutive capital raises. The Bitcoin allocation introduces volatility into an otherwise conservative treasury management approach, but even accounting for that risk, the overall capital allocation track record is disciplined relative to peers at similar clinical stages.
The dual-program structure. NASH hepatology and GI oncology. Provides portfolio diversification within a single company that is unusual at this market capitalization. Most micro-cap biotechs are single-asset companies where the entire investment thesis depends on one clinical program. Galmed has two distinct therapeutic programs targeting different diseases through the same mechanism of action. A failure in the GI oncology Phase 1/2 does not invalidate the NASH data. A setback in the semaglutide combination development does not affect the oncology program timeline. This program diversification means the probability that at least one program produces a value-creating event is meaningfully higher than the probability for any single program alone.
The institutional ownership dynamics at Galmed current valuation create conditions for significant price discovery events. Micro-cap biotechs trading near cash value with multiple clinical catalysts are the specific profile that biotech-focused hedge funds and crossover investors screen for. A single institutional purchase of 5 to 10 percent of the float at current prices would move the stock materially because the trading volume is thin and the float is small. The catalysts. Phase 1/2 GI oncology initiation, semaglutide combination partnership announcement, or any clinical data publication; are the events that trigger institutional discovery. Each catalyst that materializes without a stock price response simply compresses the spring further, because the cash floor provides downside protection while the accumulating clinical evidence builds the upside case.
The NASH therapeutic landscape has changed significantly since Galmed began its Aramchol program. Madrigal Pharmaceuticals received FDA approval for resmetirom in March 2024, making it the first approved NASH therapy. This approval validates the therapeutic area and demonstrates that the FDA will approve drugs for NASH with fibrosis, which de-risks the regulatory pathway for subsequent entrants. Aramchol mechanism is different from resmetirom. SCD1 inhibition versus THR-beta agonism. Which means it could offer complementary or additive benefit rather than competing directly. The existence of an approved therapy actually improves the development pathway for combination approaches, because clinical trials can now include an active comparator rather than requiring placebo-only controls.
Dossiers, weekly roundup editions, and podcast notes. Free. No paywall. Unsubscribe anytime.